Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $20.83 in the prior trading day, Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $21.0, up 0.82%. In other words, the price has increased by $0.82 from its previous closing price. On the day, 0.56 million shares were traded. VRDN stock price reached its highest trading level at $21.11 during the session, while it also had its lowest trading level at $20.75.
Ratios:
Our goal is to gain a better understanding of VRDN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.01 and its Current Ratio is at 11.01. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On December 19, 2024, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $37 to $27.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1714909696 and an Enterprise Value of 1363519744. For the stock, the TTM Price-to-Sale (P/S) ratio is 5716.38 while its Price-to-Book (P/B) ratio in mrq is 5.26. Its current Enterprise Value per Revenue stands at 4470.557 whereas that against EBITDA is -3.674.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.78, which has changed by -0.077733874 over the last 52 weeks, in comparison to a change of 0.15927899 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 11.20%, while the 200-Day Moving Average is calculated to be 27.37%.
Shares Statistics:
The stock has traded on average 762.40K shares per day over the past 3-months and 626310 shares per day over the last 10 days, according to various share statistics. A total of 81.65M shares are outstanding, with a floating share count of 73.55M. Insiders hold about 9.93% of the company’s shares, while institutions hold 106.23% stake in the company. Shares short for VRDN as of 1757894400 were 11000468 with a Short Ratio of 14.43, compared to 1755216000 on 11787624. Therefore, it implies a Short% of Shares Outstanding of 11000468 and a Short% of Float of 14.069999999999999.
Earnings Estimates
Viridian Therapeutics Inc (VRDN) is presently subject to a detailed evaluation by 11.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.42 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$2.96 and -$4.97 for the fiscal current year, implying an average EPS of -$4.05. EPS for the following year is -$3.97, with 11.0 analysts recommending between -$2.9 and -$4.99.
Revenue Estimates
Based on 14 analysts’ estimates, the company’s revenue will be $54.5M in the next fiscal year. The high estimate is $153M and the low estimate is $300k.
